TransEnterix Announces Ochsner Health System to Initiate Program with the Senhance Surgical System
January 08 2020 - 6:55AM
Business Wire
TransEnterix, Inc. (NYSE American:TRXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to improve minimally invasive surgery, today announced
that the Ochsner Health System has entered into an agreement to
lease and utilize a Senhance® System that has been installed at the
Ochsner Baptist* facility. This placement is one of the two
placements referenced in the Company’s January 6, 2020 press
release.
The Senhance System is the first new abdominal robotic surgery
platform to receive FDA clearance since 2000. It is the first and
only digital laparoscopic surgical platform designed to maintain
laparoscopic MIS standards while providing digital benefits such as
haptic feedback, robotic precision, comfortable ergonomics,
advanced instrumentation including, 3 mm microlaparoscopic
instruments, eye sensing camera control and reusable standard
instruments to help maintain per-procedure costs similar to
traditional laparoscopy.
“We are pleased that Ochsner Baptist Medical Center is beginning
its digital laparoscopy program using the Senhance Surgical
System,” said Anthony Fernando, president and chief executive
officer at TransEnterix. “Our system is designed to minimize
invasiveness, maximize control, and support responsible economics
for the hospital. We look forward to partnering with the surgeons
at Ochsner Baptist to advance patient care in ways that matter in
today's value-based healthcare landscape.”
“I’m excited to bring new minimally invasive technology to the
patients at Ochsner Baptist,” said Dr. George B. Morris, IV,
chairman of OB/GYN at Ochsner Baptist. “We believe new technology,
such as the Senhance Surgical System, will allow our skilled
surgeons to maximize control, offer precise surgery, and minimize
invasiveness for patients.”
“As a health system, we are continuing to drive innovation as
part of our mission to serve our patients,“ said Beth Walker, chief
executive officer Ochsner Baptist. “We evaluated the Senhance
Surgical System and believe it will be a welcome addition to our
leading offering for patients seeking advanced minimally invasive
and robotic surgery.”
*Ochsner Baptist – a campus of Ochsner Medical Center
About TransEnterix
TransEnterix is a medical device company that is digitizing the
interface between the surgeon and the patient to improve minimally
invasive surgery by addressing the clinical and economic challenges
associated with current laparoscopic and robotic options in today's
value-based healthcare environment. The Company is focused on the
commercialization of the Senhance Surgical System, which digitizes
laparoscopic minimally invasive surgery. The system allows for
robotic precision, haptic feedback, surgeon camera control via eye
sensing and improved ergonomics while offering responsible
economics. The Senhance Surgical System is available for sale in
the US, the EU, Japan and select other countries. For more
information, visit www.transenterix.com.
About Ochsner Health System
Ochsner Health System is Louisiana’s largest non-profit,
academic, healthcare system. Driven by a mission to Serve, Heal,
Lead, Educate and Innovate, coordinated clinical and hospital
patient care is provided across the region by Ochsner's 40 owned,
managed and affiliated hospitals and specialty hospitals, and more
than 100 health centers and urgent care centers. Ochsner is the #1
ranked hospital in Louisiana by U.S. News & World Report and is
recognized as a “Best Hospital” across two specialty categories
caring for patients from all 50 states and more than 70 countries
worldwide each year. Ochsner Hospital for Children is the only
facility in Louisiana to be recognized as a top 50 children’s
hospital by U.S. News & World Report for three consecutive
years. Ochsner employs nearly 25,000 employees and over 4,500
employed and affiliated physicians in over 90 medical specialties
and subspecialties and conducts more than 700 clinical research
studies. Ochsner Health System is proud to be a tobacco-free
environment. For more information, please visit ochsner.org and
follow us on Twitter and Facebook.
Forward-Looking Statements
This press release includes statements relating to the Senhance
System and the Ochsner Health System initiating a program with the
Senhance System. These statements and other statements regarding
our future plans and goals constitute "forward looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, and are
intended to qualify for the safe harbor from liability established
by the Private Securities Litigation Reform Act of 1995. Such
statements are subject to risks and uncertainties that are often
difficult to predict, are beyond our control and which may cause
results to differ materially from expectations and include whether
TransEnterix’s partnering with the surgeons at Ochsner Health
System will advance patient care in ways that matter in today’s
value-based healthcare landscape; whether surgeons at Ochsner
Baptist, using the Senhance System, will maximize control, offer
precise surgery and minimize invasiveness for patients; and whether
the Senhance System will be a welcome addition to Ochsner Baptist’s
leading offering for patients seeking advanced minimally invasive
and robotic surgery. For a discussion of the risks and
uncertainties associated with TransEnterix's business, please
review our filings with the Securities and Exchange Commission
(SEC), including our Annual Report on Form 10-K for the year ended
December 31, 2018, filed with the SEC on February 27, 2019 and our
other filings we make with the SEC. You are cautioned not to place
undue reliance on these forward looking statements, which are based
on our expectations as of the date of this press release and speak
only as of the origination date of this press release. We undertake
no obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200108005119/en/
For TransEnterix, Inc. Investor Contact: Mark Klausner, +1
443-213-0501 invest@transenterix.com or Media Contact: Terri
Clevenger, +1 203-682-8297 terri.clevenger@icrinc.com
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From Apr 2024 to May 2024
TransEnterix (AMEX:TRXC)
Historical Stock Chart
From May 2023 to May 2024